Several other research analysts have also recently commented on the company. Barclays reissued a “hold” rating and set a $64.00 price target on shares of DENTSPLY SIRONA in a research report on Sunday, January 19th. ValuEngine cut DENTSPLY SIRONA from a “hold” rating to a “sell” rating in a research report on Wednesday, October 2nd. Zacks Investment Research raised DENTSPLY SIRONA from a “hold” rating to a “buy” rating and set a $60.00 price objective for the company in a research report on Tuesday, December 10th. JPMorgan Chase & Co. cut DENTSPLY SIRONA from an “overweight” rating to a “neutral” rating and set a $65.00 price objective for the company. in a research report on Wednesday, December 11th. They noted that the move was a valuation call. Finally, HC Wainwright reaffirmed a “hold” rating and issued a $60.00 price objective on shares of DENTSPLY SIRONA in a research report on Friday, November 15th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and five have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $58.27.
Shares of NASDAQ XRAY opened at $59.66 on Friday. The stock has a 50 day moving average price of $57.66 and a 200 day moving average price of $55.09. DENTSPLY SIRONA has a 52 week low of $40.26 and a 52 week high of $60.87. The company has a debt-to-equity ratio of 0.30, a quick ratio of 1.39 and a current ratio of 2.08. The stock has a market capitalization of $13.42 billion, a PE ratio of 82.86, a price-to-earnings-growth ratio of 1.89 and a beta of 0.94.
DENTSPLY SIRONA (NASDAQ:XRAY) last issued its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $0.57 EPS for the quarter, beating the consensus estimate of $0.50 by $0.07. DENTSPLY SIRONA had a return on equity of 10.08% and a net margin of 4.08%. The firm had revenue of $962.10 million during the quarter, compared to analysts’ expectations of $940.38 million. During the same period in the prior year, the firm posted $0.38 earnings per share. The business’s quarterly revenue was up 3.6% compared to the same quarter last year. As a group, research analysts forecast that DENTSPLY SIRONA will post 2.46 EPS for the current year.
In other news, Director Michael C. Alfano sold 10,665 shares of the firm’s stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $56.27, for a total value of $600,119.55. Following the completion of the sale, the director now directly owns 15,153 shares of the company’s stock, valued at $852,659.31. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 0.62% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in XRAY. Quest Capital Management Inc. ADV bought a new position in shares of DENTSPLY SIRONA during the third quarter worth approximately $30,000. Candriam Luxembourg S.C.A. increased its stake in shares of DENTSPLY SIRONA by 55.6% during the fourth quarter. Candriam Luxembourg S.C.A. now owns 529,136 shares of the medical instruments supplier’s stock worth $30,000 after purchasing an additional 189,063 shares during the period. Rational Advisors LLC increased its stake in shares of DENTSPLY SIRONA by 102.7% during the third quarter. Rational Advisors LLC now owns 675 shares of the medical instruments supplier’s stock worth $36,000 after purchasing an additional 342 shares during the period. Coastal Investment Advisors Inc. increased its stake in shares of DENTSPLY SIRONA by 309.7% during the third quarter. Coastal Investment Advisors Inc. now owns 1,184 shares of the medical instruments supplier’s stock worth $63,000 after purchasing an additional 895 shares during the period. Finally, Huntington National Bank increased its stake in shares of DENTSPLY SIRONA by 66.0% during the fourth quarter. Huntington National Bank now owns 1,260 shares of the medical instruments supplier’s stock worth $71,000 after purchasing an additional 501 shares during the period. Institutional investors own 94.38% of the company’s stock.
DENTSPLY SIRONA Company Profile
DENTSPLY SIRONA Inc designs, develops, manufactures, and markets various dental and oral health products, and other consumable healthcare products primarily for the professional dental market worldwide. The company operates in two segments, Technologies & Equipment; and Consumables. Its dental supplies include endodontic instruments and materials, dental anesthetics, prophylaxis pastes, dental sealants, impression materials, restorative materials, tooth whiteners, and topical fluoride products; and small equipment products comprise dental hand pieces, intraoral curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers.
Featured Story: What member countries make up the G-20?
Receive News & Ratings for DENTSPLY SIRONA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA and related companies with MarketBeat.com's FREE daily email newsletter.